Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit resulting from soaring demand for its blockbuster weight reduction drug Wegovy and diabetes treatment Ozempic.Â
The revised forecast only confirms the frenzy for those weekly injections, which patients look for their ability to assist them lose significant weight over time. Ozempic and Wegovy have propelled Novo Nordisk to grow to be Europe’s most precious company.
The Danish drugmaker now expects 2023 sales growth in local currencies of 32% to 38%, from a previous outlook of 27% to 33%, in line with a press release.Â
Novo Nordisk also expects operating profit growth of 40% to 46%, from 31% to 37% previously.
The brand new sales outlook for this yr primarily reflects higher expectations for Ozempic sales within the U.S. and “gross-to-net sales adjustments for Ozempic and Wegovy within the U.S.,” in line with the discharge.
Novo Nordisk is slated to report third-quarter earnings Nov. 2.
The corporate’s U.S.-listed shares rose about 1% and touched a latest 52-week high Friday.
An Ozempic injection pen is seen on a kitchen table in Riga, Latvia, on Aug. 6, 2023.
Jaap Arriens | Nurphoto | Getty Images
